Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1 Dermatologic 1

Conditions

Skin Neoplasms 1 Recurrence 1 Neoplasms 1 Multiple Sclerosis, Relapsing-Remitting 1 Multiple Sclerosis 1 Melanoma 1 Lymphoma, T-Cell, Cutaneous 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Gliosarcoma 1 Glioblastoma 1 Carcinoma, Basal Cell 1

Interventions

Cyclophosphamide 45 Peripheral Blood Stem Cell Transplantation 43 fludarabine phosphate 42 Mycophenolic Acid 30 Whole-Body Irradiation 27 Cyclosporine 27 Busulfan 26 Tacrolimus 23 Antilymphocyte Serum 23 Methotrexate 20 Etoposide 20 romidepsin 19 Filgrastim 19 Melphalan 16 Radiotherapy 15 Flow Cytometry 15 Vorinostat 13 Methylprednisolone 13 Brentuximab Vedotin 13 Lenalidomide 12 Bexarotene 12 mogamulizumab 11 Psychiatric Rehabilitation 11 Bortezomib 11 Therapeutics 10 Rituximab 10 Gemcitabine 10 fludarabine 9 Polymerase Chain Reaction 9 Biopsy 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Lymphoma, T-Cell, Cutaneous × Dimethyl Fumarate × Clear all

NCT02546440 2023-03-31

DMF-CTCL

Universitätsmedizin Mannheim

Phase 2 Completed

DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon ⚡